

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 October 2003 (16.10.2003)

PCT

(10) International Publication Number
WO 03/084504 A2

(51) International Patent Classification⁷: **A61K 9/00**

(74) Agent: **MAIWALD, Walter**; Maiwald Patentanwalts
GmbH, Elisenhof, Elisenstrasse 3, 80335 München (DE).

(21) International Application Number: **PCT/EP03/03541**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: **4 April 2003 (04.04.2003)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
102 15 131.8 **5 April 2002 (05.04.2002)** **DE**
102 15 067.2 **5 April 2002 (05.04.2002)** **DE**

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **EURO-CELTIQUE S.A.** [LU/LU]; 122, Boulevard de la Petrusse, L-2330 Luxembourg (LU).

Published:

— *without international search report and to be republished upon receipt of that report*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BRÖGMANN, Bianca** [DE/DE]; Hinter dem Brot 4, 89073 Ulm (DE). **MÜHLAU, Silke** [DE/DE]; Basaltring 19, 65582 Diez (DE). **SPITZLEY, Christof** [DE/DE]; Ringstrasse 7a, 65627 Elbtal-Heuchelheim (DE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **MATRIX FOR SUSTAINED, INVARIANT AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS**

(57) Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.

BEST AVAILABLE COPY

WO 03/084504 A2

Matrix for sustained, invariant and independent release of active compounds

The invention concerns a storage stable pharmaceutical formulation comprising at
5 least one pharmaceutically active compound in a substantially non-swellable
diffusion matrix, wherein the compound is released from the matrix in a sustained
and invariant, and where several compounds are present, an independent manner.
With respect to its essential release characteristics the matrix is formed by amounts
of ethylcellulose and at least one fatty alcohol.

10

The invention also concerns a method for producing storage stable pharmaceutical
formulations comprising at least one pharmaceutically active compound in a non-
swellable diffusion matrix, wherein the at least one compound is released from the
matrix in a sustained and invariant manner and, where several compounds are
15 present, also an independent manner.

Sustained release formulations of pharmaceutical preparations take a central role in
the development of improved therapies. It is the intent of all sustained release
preparations to provide a longer period of pharmacological response after the
20 administration of the drug than is ordinarily experienced after the administration of
rapid release dosage forms. Sustained release pharmaceutical preparations
comprising relatively large amounts of the pharmaceutically active compound and
that release the compounds in a controlled, regulated manner over a longer period of
time (typically 2-16 hours), ensure that the frequency with which the medicine has to
25 be taken by the patient is reduced and that higher compliance by the patients is
achieved.

The longer release duration and the concomitant prolonged effect of the active
compounds, as is ensured by sustained release pharmaceutical preparations, provides
30 moreover for many therapeutic benefits that are not achieved with corresponding
short-acting, immediate release preparations. By using sustained release
pharmaceutical preparations, therapy may be continued e.g. overnight without the
necessity to interrupt the patient's sleep. This plays a role, for instance, in the

- 2 -

treatment of epilepsy patients, where the occurrence of nocturnal attacks may thus be prevented. In the same way, patients suffering from chronic pain are allowed undisturbed sleep.

- 5 From the medical-pharmacological point of view, one advantage of sustained release formulations is the very uniform active compound concentration in the blood, leading to a long-lasting effect and reduced side effects. The reduction of side effects plays a decisive role during, e.g. the use of opioids for pain therapy. Opioid-induced side-effects comprise among others the danger of an addiction developing.
- 10 As the addictive potential of an active compound is not defined by the compound itself, but rather by the way it is administered and the pharmaco-dynamic resulting therefrom (e.g. by the rate at which the brain encounters an active compound), the sustained release of an opioid analgesic can reduce the addictive potential of these active compounds (Nolte, T.: STK-Zeitschrift für angewandte Schmerztherapie,
- 15 2001, Vol. 2).

- Since sustained release formulations allow for a uniformly high active compound concentration in the blood, the bio-availability of the active compound is increased. A multitude of factors contribute to the bio-availability of an active compound. Such
- 20 factors include the active compound concentration in the respective physiological fluid (e.g. in the blood), the absorbability of the active compound across membranes (e.g. for the re-absorption in the gastro-intestinal system) and the availability of the active compound at the desired tissue site.
- 25 In order to be absorbed, for instance by the intestinal system, an active compound must be in solution. The time required for a given proportion of an active compound present in a unit dosage of a pharmaceutical preparation in order to be dissolved in the respective physiological fluid, is designated as the dissolution time, also as the release time, or release rate. The dissolution time of an active compound is
- 30 determined as the proportion of the active compound released from a unit dosage

- 3 -

form over a specified time based on a test method conducted under standardized conditions. The physiological fluid in which the dissolution time of the active compound is determined may be, e.g. the fluid of the gastro-intestinal system. The state of the art recognises many satisfactory test procedures for measuring dissolution time for pharmaceutical compositions (and correspondingly, for the release rates of the active compounds), and these test procedures are described in official compendia worldwide.

Among the various factors affecting dissolution time of pharmaceutical compositions, and thereby the release rates of active compounds, are the surface area of the pharmaceutical composition accessible to the dissolution solvent medium, the pH of the dissolution solvent medium, the solubility of the active compound in the dissolution solvent medium and the saturation concentration of dissolved materials in the dissolution solvent medium.

Despite the diverse factors that influence the dissolution of the active compound in the dissolution medium as well as the absorption of the active compound, a strong correlation has been established between the *in vitro* dissolution time determined for a pharmaceutical preparation and the *in vivo* bio-availability of the active compound. This correlation is so well established that the dissolution time (release rate of the active compound) is considered to be a generally accepted criterion for the bio-availability of the active compound of a pharmaceutical preparation. In view of this correlation, it becomes clear that the release rate as determined for the active compound of a pharmaceutical formulation is one of the important fundamental characteristics that has to be considered when evaluating sustained release formulations.

Different approaches are known from the prior art that allow the formulation of sustained release pharmaceutical preparations. These approaches have in common that the active compound is combined with additives to shape bodies, such as tablets

- 4 -

- or dragées, with the additives forming a release or dissolution barrier for the active compound. Depending on the nature of the release barriers, different sustained release methods can be distinguished. There are, e.g. osmotic systems, systems by which retardation is achieved through coatings, or systems in which the active compounds are embedded in waxes, polymethacrylates, gel-formers or silicic acids. There are moreover the so-called matrix forms, which are of fundamental importance when formulating sustained release pharmaceutical preparations. Matrix means a shaped body comprising the active compound bound to additives which are as inert as possible. Depending on the type of matrix, one can differentiate between e.g. swellable or non-swellable matrices. Moreover matrices differ depending on whether the active compound is released by pure diffusion or by erosion of the matrix (U. Schöffling, Arzneiformenlehre, 1998, 3rd edition, Deutscher Apotheker-Verlag, Stuttgart).
- 15 The additives used for the preparation of sustained release pharmaceutical preparations frequently lead to problems concerning the stability of the pharmaceutical preparation after prolonged storage times. For e.g. waxes, it has been shown that they are subject to changes, so that extensive precautionary steps have to be taken even at the time of production, in order to prevent changes during the storage time. If film coatings consisting of polymers produced from aqueous dispersions are used for retardation, these pharmaceutical preparations also frequently display problems with storage stability.
- 25 There are prior art sustained release pharmaceutical preparations having so-called controlled release of the pharmaceutically active compound, i.e. the release of the active compound is not only prolonged, but moreover can be adjusted to a predetermined release rate. Depending on which polymers (hydroxyalkylcelluloses, polymethacrylates or e.g. alkylcelluloses) are used for the production of e.g. matrix-based sustained release pharmaceutical preparations with controlled release, the

- 5 -

release behaviour of the respective pharmaceutically active compounds may differ, the release behaviour of the active compound frequently being difficult to predict.

Generally, it should be ensured that pharmaceutical preparations of a given
5 pharmaceutical formulation release the respective compound always with reproducible equal release rates or release profiles, even if the formulation comprises different absolute amounts of the active compounds. However, due to the stability problems, which are caused by the components responsible for the sustained release, this is not guaranteed.

10

There is a large number of sustained release pharmaceutical preparations for different therapeutic applications that frequently contain only one active compound. The medicament Oxygesic®, which is used in pain therapy, contains e.g. oxycodone as the only analgetically active compound. The medicament Kapanol®, which is also
15 used in pain therapy, comprises morphine sulfate as analgetically active compound.

20

As the long term application opioid analgesics such as oxycodone may go along with the development of side effects such as breath depression and obstipation, co-treatment of patients with opioid antagonists that specifically counteract the opioid-induced side effects may be necessary. If patients seeking pain release are treated with preparations comprising an opioid analgesic, simultaneous treatment with preparations comprising antagonists such as naltrexone or naloxone may be desirable in order to counteract the aforementioned side effects. If the opioid-containing preparation is a sustained release preparation, the antagonist-preparation should also
25 provide for a sustained release as otherwise development of side effects may not effectively be repressed. However, sustained release formulations of e.g. naloxone alone are not available on the market.

30

In the treatment of different symptoms it is therefore a common strategy to counteract the side-effects provoked by an active compound by simultaneous

administration of another compound that selectively reduces these side-effects. If e.g. opioid analgesics are used in pain therapy, side-effects such as obstipation and breath depression may occur in addition to the danger of the development of dependency and addiction as already mentioned. Various attempts have therefore
5 been made to eliminate, or at least significantly reduce, the addictive and habit-forming potential of opioid analgesics as well as their other side-effects, by the simultaneous administration of antagonists which counteract the opioid analgesic.

In view of the significant advantages that such combination preparations have and
10 due to the aforementioned general advantages of sustained release pharmaceutical preparations, there is a great need for sustained release formulations of such combination preparations. Sustained release formulations of combination preparations should combine in an ideal manner the positive, synergistic effects of the different active compounds with the long-lasting release and the correspondingly
15 increased period of effectiveness.

One example of such a combination preparation which releases several compounds in a sustained manner is Valoron® from Gödecke, which comprises tilidine as an analgetically active compound and naloxone as antagonist.

20

However, one problem that frequently occurs with combination preparations is that active compounds of different chemical structures and physical characteristics have to be combined in one matrix. Such a combination usually leads to different release profiles for both compounds. The release of both compounds with the same release
25 profiles can, however, be highly desirable from a medical point of view. Moreover, it may be preferable that both compounds are released from the same matrix, since in this way e.g. tablets may be produced which can be split. Such tablets are suitable for individual dosing and the production process of the corresponding preparations can be significantly simplified. Another aspect is that with several compounds of
30 different structures being present, the compounds may differ with respect to their

- 7 -

stability in the matrix over a longer storage period. Additionally, the change of amount of one compound may change the release profile of other compounds in an unpredictable manner in such combination preparations, resulting in significant expenditure in the production of preparations having different amounts of the active compounds, since one cannot infer from the release behaviour of one preparation the release behaviour of another one.

Generally, medicaments have to be formulated in a such a way that the active compounds are stable as long as possible under standard storage conditions.

10 Medicaments also have to be formulation in such a way that the intended release profiles of the active compounds do not change during long-term storage.

It should also be ensured that the release profile of one active compound of a given sustained release formulation does not change depending on the amount of the active compound. This applies to the case where a single compound or also several compounds are present in the pharmaceutical preparation.

Additionally (also in the case of active compound combinations), the release profile of each single compound should be selectable as required. The measures to be taken in order to achieve this should not prevent, or even hamper the release profiles of additional active compounds, e.g. in the case of combinations of different active compounds, being chosen as required. Consequently, there should be no mutual dependency of the release profiles.

25 For a variety of therapeutic applications there is a great need for combination preparations. Particularly for pain therapy combination preparations are required that consist of opioid analgesics and corresponding antagonists, where the respective pharmaceutical preparations release both compounds in a sustained manner and also possess the aforementioned characteristics. Matrix formulations that ensure a sustained release of active compounds in general and of opioid analgesics and their

30

- 8 -

antagonists in particular and that possess the aforementioned characteristics are not known from prior art.

5 German patent application DE 43 25 465 A1 concerns the treatment of side-effects during pain therapy by a preparation consisting of an opioid agonist and an antagonist. The characterizing feature of this disclosure is that the antagonist must not be released in a sustained manner while the agonist should be released in a sustained manner.

10 International patent application WO 99/32120 is also concerned with a preparation consisting of an opioid analgesic and an antagonist. According to this disclosure, both compounds should be released in a sustained manner. Storage stability and the mutual dependency of the release profiles of compounds is, however, not subject matter of this application.

15

The aforementioned pain-relief medicament Valoron® is a tilidine/naloxone-combination. According to the manufacturer's data it is a formulation from which both active compounds are released in a sustained manner. The matrix used comprises a relevant part of water-swellaable material (hydroxypropylmethylcellulose (HPMC)) and has therefore to be considered as a swellaable (and possibly partially
20 erosive) diffusion matrix. The disadvantage of this known formulation is that tilidine and naloxone, given identical mass ratios but different absolute amounts, display different release profiles, if the release is measured for certain pH values. The release rates of the agonist and the antagonist are not independent of each other,
25 which is probably due to the sustained release formulation used. Accordingly, it is necessary for the physician to carry out extensive titration experiments for each individual patient if he wants to increase the dosage, even though he does not change the mass ratio of tilidine:naloxone, since he cannot assume that the release profiles of both components will remain constant. The range of therapeutically usable amounts
30 of the analgesic available to the physician is therefore limited.

- 9 -

One objective of the present invention is to provide formulations for a pharmaceutical preparation that ensure that the active compounds of the preparations are released in a sustained manner, that are stable over a long storage period, and
5 where the release of one compound does not change even when different amounts of the active compound are used. A further objective of the invention is to provide formulations for pharmaceutical preparations that display the above-mentioned characteristics and that show no mutual dependency of the release profiles of the active compounds.

10 Another objective of the present invention is to provide methods for producing pharmaceutical formulations comprising at least one pharmaceutically active compound and from which the compounds are released in a sustained, reproducibly invariant and, where several compounds are present, independent manner. Such
15 formulations should remain stable even after longer storage periods.

A particular objective of the present invention is to provide formulations for pharmaceutical preparations that comprise the opioid antagonist naloxone, wherein the active compound is stable over a long storage time and is released from the
20 preparation in a sustained and reproducibly invariant manner. Formulations that achieve this, are not known from prior art.

An additional objective of the present invention is to provide formulations for pharmaceutical preparations for pain therapy comprising at least one opioid analgesic
25 and at least one antagonist counteracting the opioid analgesic, wherein the formulation is stable over a long storage period and wherein the active compounds are released from the preparation independently of each other in a sustained and reproducibly invariant manner.

- 10 -

The features of the independent claims serve to attain these and further objectives which can be noted from the following description of the invention. Preferred embodiments of the invention are defined in the dependent claims.

5 According to the invention the objectives are solved by providing a pharmaceutical formulation comprising at least one pharmaceutically active compound in a substantially non-swellable diffusion matrix, wherein the matrix is formed with respect to its essential release characteristics by ethylcellulose and at least one fatty alcohol.

10

It has surprisingly been found that only formulations having a (substantially) non-swellable diffusion matrix based on ethylcellulose and at least one fatty alcohol ensure a sustained, invariant and, if several active compounds are present, independent release of the active compounds.

15

The inventive matrix formulation which is stable over long storage periods permanently ensures that the active compounds are always released in predetermined percentages and that the release rates do not influence each other. For combination preparations that e.g. comprise opioid analgesics and the respective antagonists, 20 abuse of the medicaments, which presupposes that the agonist can be selectively extracted from the formulation, is prevented.

The formulation according to the invention disables selective extraction of the agonist from the preparation without the corresponding amount of the antagonist, 25 regardless of the absolute and relative amount of agonist and antagonist chosen. Furthermore, such preparations reduce side-effects which usually occur during the application of opioids. Since the active compounds are released from the same matrix, a simplified and more efficient production process is made possible. This also applies for combination preparations comprising other compounds other than 30 opioids analgesics or antagonists thereof.

- 11 -

Moreover, the inventive formulation of a medicament ensures that given identical relative amounts, the active compounds show the same release profiles regardless of the absolute amount present. Such independent release behaviour provides the physician with a wide range of usable absolute amounts of the active compounds, where the optimal compound ratio (e.g. for opioid agonist/antagonist ratios) is known. It is thus possible to comfortably adjust the dosage for each individual patient, either by increasing the dosage gradually or, if necessary, by reducing the dosage gradually. This ability to adjust the dosage for the individual patient is extremely useful from a medical point of view, as is the increased compliance.

The inventive formulations also allow for the production of pharmaceutical preparations that release active compounds of different structures with the same release profiles.

Since the pre-determinable release of active compounds from the inventive formulation does not change regardless of the amount and the number of compounds and takes place from the same matrix, once a combination of active compounds has been established preparations with different amounts of active compound can be produced without significant technical effort and corresponding preparations for different therapeutically relevant areas may be provided.

The characterizing features of the present invention are the sustained, invariant, and if several active compounds are present, independent release of the active compounds from a non-swellable (at least not to an extent which is relevant for the release) diffusion matrix with the matrix being determined with respect to its essential release characteristics by ethylcellulose and at least one fatty alcohol and the active compounds remaining stable over long storage periods.

- 12 -

According to the present invention "sustained" or "controlled sustained release" or "retardation" means that pharmaceutically active substances are released from a medicament over a longer period of time than is the case with known formulations for immediate release. Preferably, the release takes place over a time period of two
5 to twenty-four hours, of two to twenty hours, especially preferably over a time period of two to sixteen hours or two to twelve hours, with the specifications satisfying legal requirements.

In the context of the present invention, "sustained release" does not mean that the
10 active compounds are released from the formulation or the medicament in a pH-dependent manner. According to the invention, the term "sustained release" refers to the release of active compounds from a medicament over an extended period of time. It does not imply the controlled release at a defined place; it therefore does not mean that the active compounds are either released only in the stomach, or only in the
15 intestine. Correspondingly, the release of the active compounds from the inventive formulations occurs preferably pH-independently.

(Of course, a pH dependent release at a defined place could individually be achieved by, e.g. enteric coating of the medicament, although this presently seems not to be advantageous).

20

According to the invention, "independent release" means that, given the presence of at least two active compounds, a change of the absolute amount of one compound does not influence the release profiles of the other compounds so that the release profiles of the other compounds are not changed. For formulations according to the
25 invention such an independent release behaviour is independent of the pH value, for which the release is measured, or of the production process. The pH independency particularly applies to the acidic range, i.e. for pH values < 7. The release profile (or release behaviour) is defined as the change of the release of the active compound from the formulation with time, with the amount of each active compound released

- 13 -

provided in percents of the total amount of the active compound. The release profile is determined by known tests.

Specifically, this means that for example the release profile of oxycodone, as it is
5 observed for an oxycodone/naloxone-combination with 12 milligrams oxycodone and 4 milligrams naloxone, does not change, if a corresponding preparation with the same formulation contains 12 milligrams oxycodone, but 6 milligrams naloxone.

The independent release feature preferably refers to the situation where preparations
10 of substantially equal composition are compared for the release profile. Preparations of substantially equal composition have different amounts of the active compounds but are otherwise basically the same with respect the components of the composition which essentially influence the release behaviour.

15 If e.g. the above-mentioned preparations are compared (with the first preparation comprising 12 mg oxycodone and 4 mg naloxone and the second preparation comprising 12 mg oxycodone and 6 mg naloxone) both preparations, provided that they have the same total weight, will provide for the same release profile for oxycodone and naloxone if the difference in the naloxone amount is replaced by a
20 component in the formulation that typically does not influence the release behaviour. As shown in the Example section, the difference in the amount of naloxone may be replaced by a typical pharmaceutically inert filler such as lactose without changing the release profiles.

25 The person skilled in the art is well aware that if the amount of the active compound in which two preparations differ is replaced by a substance that is essential for the release behaviour of the formulation, such as ethylcellulose or a fatty alcohol, differences in the release behaviour may occur. Thus, the independent release feature preferably applies to formulations that have different amounts of the active
30 compounds but are otherwise identical or at least highly similar with respect to the

- 14 -

components that essentially influence the release behaviour (given that formulations of the same total weight are compared).

According to the invention, "invariant release behaviour" or "invariant release
5 profile" is defined so that the percentage of the absolute amount of each active
compound released per time unit does not significantly change and remains
sufficiently constant (and thus does not substantially change) if absolute amounts are
changed. Sufficiently constant percentages mean that the percentage released per
time unit deviates from a mean value by not more than 20%, preferably by not more
10 than 15% and especially preferably by not more than 10%. The mean value is
calculated from six measurements of the release profile. Of course, the amount
released per time unit has to satisfy the legal and regulatory requirements.

Specifically, this means for example that given an oxycodone/naloxone combination
15 of 12 mg oxycodone and 4 mg naloxone, during the first 4 hours 25% oxycodone and
20% naloxone are released. If the oxycodone/naloxone combination instead contains
24 mg oxycodone and 8 mg naloxone, during the first 4 hours also 25% oxycodone
and 20% naloxone will be released. In both cases the deviation will not be more than
20% from the mean value (which in this case is 25% oxycodone and 20% naloxone).

20 As outlined for the independent release behaviour, the invariant release feature also
preferably refers to a situation where preparations of substantially equal composition
are compared. Such preparation differ with respect to the amount of the active
compounds, but are of the same or at least highly similar composition with respect to
25 the release-influencing components of the preparation. Typically, the difference in
the amount of an active compound will be replaced by the amount of a pharma-
ceutical inert excipient which does not substantially influence the release behaviour
of the preparation. Such a pharmaceutical excipient may be lactose, which is a
typical filler in pharmaceutical preparations. The person skilled in the art is well
30 aware that the invariant release feature may not apply to preparations where the

- 15 -

difference in the amount of an active compound is replaced by substances that are known to essentially influence the release behaviour of the preparation, such as ethylcellulose or fatty alcohols.

- 5 In the Example section it is set out that if one preparation comprises 20 mg oxycodone and 1 mg naloxone or 20 mg oxycodone and 10 mg naloxone, with the difference in naloxone being replaced by lactose, that the two preparations of identical weight provide for the same release profiles, so that they exhibit a sustained, invariant and independent release behaviour.

10

According to the invention "storage stable" or "storage stability" means that upon storage under standard conditions (at least two years at room temperature and usual humidity) the amounts of the active compounds of a medicament formulation do not deviate from the initial amounts by more than the values given in the specification or

15 the guidelines of the common Pharmacopoeias. According to the invention, storage stability also means that a preparation produced according to the invention can be stored under standard conditions (60% relative humidity, 25°C) as it is required for admission to the market.

- 20 According to the invention, "storage stable" or "time stable" also means that after storage under standard conditions the active compounds show release profiles as they would upon immediate use without storage. According to the invention, the admissible fluctuations with respect to the release profile are characterized in that the amount released per time unit fluctuates by no more than 20%, preferably no more
- 25 than 15% and especially preferably no more than 10 %, with respect to a mean value. The mean value is calculated from six measurements of the release profile.

The term "storage stable" refers to the active compound as well as to the other components within the inventive formulation and therefore also to the formulation as

30 a whole.

- 16 -

Preferably, the release of the active compounds from a sustained release formulation is determined by the Basket Method according to USP at pH 1.2 or pH 6.5 with HPLC.

5

Storage stability is preferably determined by the Basket Method according to USP at pH 1.2 with HPLC.

10 According to the invention, the term "formulation" refers to the preparation of a pharmaceutically active substance with additives (formulation aids) with the aim of enabling an optimal release, distribution and development of activity of the active compound for the respective applications.

15 According to the invention, a "non-swellable" or "substantially non-swellable" diffusion matrix is a matrix formulation for which the release of the active compounds is not influenced (or at least not to a relevant degree) by swelling of the matrix (particularly in the physiological fluids of the relevant target sites in the patient's body).

20 According to the invention, the term "substantially non-swellable" diffusion matrix also refers to a matrix whose volume will increase by approximately 300%, preferably by approximately 200%, more preferably by approximately 100%, by approximately 75% or by approximately 50%, even more preferably by approximately 30% or by approximately 20% and most preferably by approximately
25 15%, by approximately 10%, by approximately 5% or by approximately 1% in aqueous solutions (and particularly in the physiological fluids of the relevant target sites in the patient's body).

It has now surprisingly been found that formulations for medicaments with a
30 substantially non-swellable diffusion matrix allow for a sustained, invariant and,

- 17 -

where several compounds are present, independent release of the active compounds, when the diffusion matrix comprises ethylcellulose as the matrix-scaffold-forming substance and is moreover determined with respect to its essential release characteristics by ethylcellulose and/or at least one fatty alcohol. Additionally, such formulations are characterized by good storage stability. Given the present knowledge, mainly formulations with such a diffusion matrix allow to release the active compounds in the aforementioned inventive manner. Formulations with a (substantially) swellable diffusion matrix or an erosive matrix are currently not considered to be suitable for that.

10

Therefore, water-swellaable substances and particularly water-soluble polymers may generally not be used as scaffold-forming substances for the production of matrices for formulations in accordance with the invention. Particularly, common matrix-forming polymers such as polyvinylpyrrolidone, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, poly(vinylalcohols), alginates, hydrated hydroxyalkylcellulose and hydroxypropylmethylcelluloseether are currently not considered to be suitable for the production of formulations in accordance with the invention.

15

Scaffold-forming substances that can form non-swellaable diffusion matrices may be used for the production of formulations in accordance with the invention if they provide for a release behaviour of the active compound in accordance with the invention, i.e. for a sustained, invariant and, where several components are present, independent release, as well as for storage stability of the formulation. Water-insoluble polymers, that are commonly used for the production of matrix-based sustained release pharmaceutical preparations may also not be used straightforwardly for the production of formulations in accordance with the invention. Common scaffold-forming substances such as acrylic acid and methacrylic acid copolymers, methylmethacrylate copolymers, ethoxyethylmethacrylate copolymers, cyanoethylmethacrylate, aminoalkylmethacrylate copolymers, poly(acrylic acid),

25

30

- 18 -

poly(methacrylic acid), polymethacrylates, poly(methylmethacrylate) copolymers, polyacrylamine or alginic acid are currently not considered to be suitable for the production of formulations in accordance with the invention.

5 Matrices which are based on polymethacrylates (as e.g. Eudragit® RS30D and Eudragit® RL30D) or comprise relevant amounts of water-swellaable material, particularly of hydroxyalkylcellulose such as HPMC will currently not be considered usable in accordance with the invention.

10 Currently, alkylcelluloses will generally also not be considered for the production of formulations in accordance with the invention. Propylcellulose e.g. is of too lipophilic character to produce matrices with release characteristics in accordance with the invention. Methylcellulose is also not suitable for the formulations in accordance with the invention.

15

In accordance with the invention, the matrix that ensures the sustained release of the active compound will be selected in such a way that the release of the active compounds takes place in a sustained, invariant and, if several compounds are present, independent manner, and that the formulation is storage stable. Preferably
20 such matrices comprise polymers based on ethylcellulose, with ethylcellulose being an especially preferred polymer. Specifically preferred are matrices comprising polymers available on the market under the trademark Surelease®. Particularly preferred is the use of Surelease® E-7-7050.

25 Other retardation methods, such as e.g. film coatings that ensure a sustained release, are currently not considered to be suitable for production of formulations that provide for a release behaviour of the active compounds which is in accordance with the invention. Furthermore, they are not considered to be suitable for production of formulations that ensure that the formulation is storage stable.

30

- 19 -

For formulations in accordance with the invention which comprise a non-swelling diffusion matrix on an ethylcellulose basis, the amount of ethylcellulose (or Surelease® E-7-7050) in the matrix will vary between 1-15%, preferably between 3-12%, particularly preferably between 5-9% and even more preferably between 6-8%.

- 5 The percentages indicating the amount of ethylcellulose (or Surelease®) with respect to the total weight of the preparation.

Formulations in accordance with the preparation preferably comprise a fatty alcohol as the second component which has a sustained release effect besides ethylcellulose.

- 10 Fatty alcohols may comprise lauryl, myristyl, stearyl, cetylstearyl, ceryl and/or cetylalcohol. Preferably, stearyl and/or cetylalcohol will be used. The amount of fatty alcohol in the matrix will be between 5-30%, preferably between 10-25% and particularly preferably between 15-20%. Particularly preferred is an amount of fatty alcohol of substantially 20% (if the matrix is produced by spray granulation) or of
- 15 substantially 18% (if the matrix is produced by extrusion). All percentages indicating the amount of fatty alcohol refer to the total weight of the preparation.

Formulations with release behaviour according to the invention comprise in particular matrices comprising ethylcellulose and at least one fatty alcohol as the

20 components that essentially influence the release characteristics of the matrix. The amount of ethylcellulose and the at least one fatty alcohol may vary significantly, so that preparations with different release profiles may be achieved. Even though the inventive preparations will usually comprise both of the aforementioned components, in some cases it may be preferred that the preparations comprise only ethylcellulose

25 or the fatty alcohol(s) as the release determining components.

- Formulations in accordance with the invention may comprise further components which have a sustained release effect if required. However, it has to be ensured that the release of the active compounds from the formulation and the storage stability of
- 30 the formulation are in accordance with the invention and are not negatively

- 20 -

influenced. Such additional components with sustained release effect may comprise polyalkylene glycols and particularly preferably polyethylene glycols.

5 According to the invention, formulations that provide a release of the active compounds in accordance with the invention may comprise, besides the matrix forming polymers, fillers and additional substances, such as granulating aids, lubricants, dyes, flowing agents and plasticizers.

10 Lactose, glucose or saccharose, starches and their hydrolysates, microcrystalline cellulose, cellactose, sugar alcohols such as sorbitol or mannitol, poorly soluble calcium salts like calciumhydrogenphosphate, dicalcium- or tricalciumphosphate may be used as fillers.

15 Povidone may be used as granulating aid.

Highly-disperse silica (Aerosil®), talcum, corn starch, magnesium oxide and magnesium- and/or calcium stearate may preferably be used as flowing agents or lubricants.

20 Magnesium stearate and/or calcium stearate can preferably be used as lubricants. Fatty acids like stearic acid, or fats like hydrated castor oil can also preferably be used.

25 Polyethylene glycols and fatty alcohols like cetyl and/or stearyl alcohol and/or cetostearyl alcohol can also be used as additional substances that influence retardation.

30 Other pharmaceutically acceptable excipients which are known in the art, such as surfactants, conserving agents, diluents, granulating aids, colorants, aromatic compounds, detergents, buffers and/or anti-sticking agents may also be comprised in

- 21 -

the sustained release matrix, if the formulation still provides for a release behaviour in accordance with the invention, i.e. a sustained, invariant and, if several compounds are present, independent release. Such formulations also have to provide good storage stability of the active compounds within the matrix.

5

If fillers and additional substances such as dyes and the mentioned lubricants, flowing agents and plasticizers are used, care has to be taken that according to the invention only such combinations together with the matrix forming substance and/or the matrix forming substances are used, which ensure release profiles of the active compounds in accordance with the invention.

10

All these additional components of the formulations will be chosen in such a way that the release matrix receives the character of a substantially non-water- or non-buffer-swellaable and non-erosive diffusion matrix.

15

According to the invention, a formulation is especially preferred that comprises ethylcellulose or Surelease® E-7-7050 as a matrix-building substance, stearyl alcohol as fatty alcohol, magnesium stearate as lubricant, lactose as filler and povidone as a granulating aid.

20

Matrices that are in accordance with the invention can be used to produce preparations that release active compounds in a sustained, independent and invariant manner and that release equal amounts of the active compounds per time unit. Specifically, this means that in the case of a oxycodone/naloxone combination containing 12 mg oxycodone und 4 mg naloxone, 25% oxycodone and 25% naloxone are released within the first 4 hours. Correspondingly, in the case of a oxycodone/naloxone combination containing 24 mg oxycodone and 8 mg naloxone, 25% oxycodone and 25% naloxone are released during the first 4 hours, with the deviation in both cases being no more than 20% of the mean value (which in this case is 25% oxycodone or naloxone).

30

- 22 -

Such an equal release behaviour for both active compounds may be desirable for medical aspects.

- 5 A preferred embodiment of the invention relates to preparations that release 1% to 40%, preferably 5% to 35%, more preferably between 10% and 30% and even more preferably between 15% and 25% of oxycodone and/or naloxone after 15 minutes. In other preferred embodiments of the invention, 15% to 20%, 20% to 25%, approximately 15%, approximately 20% or approximately 25% of oxycodone and/or
10 naloxone are released after 15 minutes.

- Another preferred embodiment of the invention relates to preparations that release between 25% to 65%, preferably between 30% to 60%, more preferably between 35% to 55% and even more preferably between 40% to 50% of oxycodone and/or
15 naloxone after one hour. Preferred embodiments of the invention also relate to preparations that release between 40% to 45%, 45% to 50%, approximately 40%, approximately 45% or approximately 50% of oxycodone and/or naloxone after one hour.

- 20 Yet another preferred embodiment of the invention relates to preparations that release between 40% to 85%, preferably between 45% to 80%, more preferably between 45% to 75% and even more preferably between 45% to 55%, 50% to 60%, 55% to 65%, 65% to 75% or 75% to 85% of oxycodone and/or naloxone after 2 hours. Preferred embodiments also comprise preparations that release approximately
25 45%, approximately 50%, approximately 55%, approximately 60%, approximately 65%, approximately 70%, approximately 75%, approximately 80% or approximately 85% of oxycodone and/or naloxone after 2 hours.

- One preferred embodiment of the invention relates to preparations that release 60%
30 to 100%, preferably between 75% to 95%, more preferably between 80% to 95%,

and even more preferably between 80% to 90% of oxycodone and/or naloxone after 4 hours. Preferred embodiments of the invention also relate to preparations that release between 80% to 85%, 85% to 90%, approximately 80%, approximately 85% or approximately 90% of oxycodone and/or naloxone after 4 hours.

5

One preferred embodiment of the invention also relates to preparations that release between 65% to 100%, preferably between 75% to 100%, more preferably between 80% to 95% and even more preferably between 80% to 85%, between 85% to 90% or between 90% to 95% of oxycodone and/or naloxone after 7 hours. Preferred
10 embodiments of the invention also relate to preparations that release approximately 80%, approximately 85%, approximately 90% or approximately 95% of oxycodone and/or naloxone after 7 hours.

15

Yet another preferred embodiment of the invention relates to preparations that release between 85% to 100%, preferably between 90% to 100%, more preferably between 95% to 100% and even more preferably approximately 95% or 100% of oxycodone and/or naloxone after 12 hours.

20

Preparations in accordance with the invention can be produced as all common application forms which, on principle, are suitable for retardation formulations and which ensure that the active compounds are released in a manner in accordance with the invention. Especially suitable are tablets, multi-layer tablets and capsules. Additional application forms like granules or powders can be used, with only those applications forms being admissible that provide a sufficient retardation and a release
25 behaviour in accordance with the invention.

30

Pharmaceutical preparations may also comprise film coatings. However, it has to be ensured that the film coatings do not negatively influence the release properties of the active compounds from the matrix and the storage stability of the active compounds within the matrix. Such film coatings may be colored or may comprise a

- 24 -

initial dosage of the active compounds if required. The active compounds of this initial dosage will be immediately released so that the therapeutically effective blood plasma level is reached very quickly. It has to be ensured that, by coating the preparations in accordance with the invention, the release behaviour of the active compounds is not negatively influenced.

The active compounds that are comprised within the formulation in accordance with the invention and which are released in a sustained, invariant and, if several compounds are present, independent manner from the inventive matrix and which are also storage stable within the matrix, are not limited to a special class of compounds.

Pharmaceutically active compounds according to the present invention thus comprise antipyretic, analgesic and anti-inflammatory agents such as indomethacin, aspirin, diclofenac, ibuprofen, antiulcer agents such as sulpiride, coronary vasodilators such as nifedipine, peripheral vasodilators such as ifenprodil tartrate, antibiotics such as ampicillin, chloramphenicol or erythromycin, synthetic antimicrobial agents such as nalidixic acid, antispasmodic agents such as propantheline bromide, antitussive and antiasthmatic agents such as theophylline or aminophylline, bronchodilators such as diprophylline, diuretics such as furosemide, muscle relaxants such as chlorphenesin carbamate, cerebral metabolism improving agents such as meclofenoxate hydrochloride, minor tranquilizers such as oxazolam, diazepam or clotiazepam, major tranquilizers such as sulpiride, beta-blockers such as pindolol, antiarrhythmic agents such as procainamide hydrochloride, anticoagulants such as ticlopidine hydrochloride, antiepileptics such as phenytoin, antihistaminics such as chlorpheniramine maleate, antiemetics such as difenidol hydrochloride, antihypertensive agents such as dimethylaminoethyl reserpilate hydrochloride, sympathomimetic agents such as dihydroergotamine mesilate, expectorants such as bromhexine hydrochloride, oral antidiabetic agents such as glibenclamide, cardiovascular system drugs such as ubidecarenone, iron preparations such as ferrous sulfate, non steroidal anti-inflammatory drugs or vitamins. Particularly preferred are

- 25 -

analgesics comprising the group of opiates and opioids such as oxycodone, morphine, dihydrocodeine, oxymorphone, buprenorphine or tramadol. Also preferred are analgesic antagonists such as naltrexone or naloxone. Other opioid agonists and antagonists can be found, e.g. in WO 99/32119.

5

Particularly preferred are formulations in accordance with the invention that comprise opioid analgesics (opioid agonists) and/or opioid antagonists as pharmaceutically active compounds.

- 10 According to the invention, opioid analgesics or opioid agonists comprise all compounds that belong to class NO2A of opioid analgesics according to the ATC Classification of the WHO, and that display an analgesic effect upon application in accordance with the invention. Preferably, an opioid agonist is selected from the group of morphine, oxycodone, hydromorphone, propoxyphene, nicomorphine,
15 dihydrocodeine, diamorphine, papaveretum, codeine, ethylmorphine, phenylpiperidine and derivatives thereof, methadone, dextropropoxyphene, buprenorphine, pentazocine, tilidine, tramadol, hydrocodone. Further examples for useable analgesics according to the invention are meperidine, oxymorphone, alphaprodine, anileridine, dextromoramide, metopone, levorphanol, phenazocine,
20 etoheptazine, propiram, profadol, phenampromide, thiambuten, pholcodeine, codeine, dihydrocodeinon, fentanyl, 3-trans-dimethylamino-4-phenyl-4-trans-carbethoxy- Λ' -cyclohexen, 3-dimethylamino-0-(4-methoxyphenyl-carbamoyl)-propiophenone oxime, (-) β -2'-hydroxy-2, 9-dimethyl-5-phenyl-6, 7-benzomorphane, (-)2'-hydroxy-2-(3-methyl-2-butenyl)-9-methyl-5-phenyl-6, 7-benzomorphane,
25 pirinitramide, (-) α -5,9-diethyl-2' hydroxy-2-methyl-6, 7-benzomorphane, ethyl 1-(2-dimethylaminoethyl)-4,5,6,7-tetrahydro-3-methyl-4-oxo-6-phenyl-indol-2-carboxylate, 1-benzoylmethyl-2, 3-dimethyl-3-(m-hydroxy-phenyl)-piperidine, N-allyl-7 α (1-R-hydroxy-1-methylbutyl)-6,14-endo-ethanotetrahydronororipavine, (-)2'-hydroxy-2-methyl-6,7-benzomorphane, noracylmethadol, phenoperidine, α -d1-

- 26 -

methadol, α -1-methadol, β -d1-acetylmethadol, α -1-acetylmethadol and β -1-acetylmethadol. These lists are not to be understood as exclusive.

Especially preferred analgesically effective opiod agonists are oxycodone,
5 hydrocodone, hydromorphone, morphine, codeine, dihydrocodeine, methadone, oxymorphone, fentanyl and sufentanyl. Specifically, the opioid agonist is oxycodone.

According to the invention, antagonists comprise such compounds that counteract
10 opioid agonists (as defined earlier). Such compounds can also be found in the ATC Classification of the WHO. According to the invention, compounds are preferred that upon application in accordance with the invention decrease the side effects, the habituation effects and the addictive potential caused by the opioid agonists. Antagonists can comprise among others, naltrexone, naloxone, nalmeferne,
15 nalorphine, nalbuphine, naloxoneazinen, methylnaltrexone, ketylcyclazocine, norbinaltorphimine, naltrindol, 6- β -naloxol and 6- β -naltrexol.

Especially preferred antagonists comprise naltrexone, nalmeferne and naloxone. Specifically preferred as an antagonist is naloxone.

20

According to the invention, formulations with a combination of oxycodone as agonist and naloxone as antagonist are particularly preferred. The agonist is preferably in excess compared to the antagonist. The excess of the agonist is defined
25 based on the amount of the unit dosage of the antagonist present in the combination preparation. The extent of the excess of the opioid agonist is usually given in terms of the weight ratio of agonist to antagonist.

In the case of oxycodone and naloxone, preferred weight ratios of agonist to antagonist lie within a weight ratio range of 25:1 at maximum, especially preferred
30 are the weight ratio ranges 15:1, 10:1, 5:1, 4:1, 3:1, 2:1 and 1:1.

- 27 -

The absolute amounts of agonist and antagonist to be used depend on the choice of the active compounds. According to the invention, care has to be taken that agonist and antagonist are released from the pharmaceutical preparation that has been
5 formulated for sustained release, only in an independent and invariant manner.

If oxycodone and naloxone are used for a combination preparation, preferably between 10 and 150 mg, especially preferably between 10 and 80 mg of oxycodone (typical amounts for use) and preferably between 1 and 50 mg naloxone per unit
10 dosage are used.

In other preferred embodiments of the invention, the preparations may comprise between 5 and 50 mg of oxycodone, between 10 and 40 mg of oxycodone, between 10 and 30 mg of oxycodone or approximately 20 mg of oxycodone. Preferred
15 embodiments of the invention may also comprise preparations with between 1 and 40 mg naloxone, 1 and 30 mg naloxone, 1 and 20 mg naloxone or between 1 and 10 mg naloxone per unit dosage.

According to the invention, the ratio between oxycodone and naloxone has to be
20 chosen in such a way that release profiles for both active substances in accordance with the invention are guaranteed and that the agonist can display its analgesic effect while the amount of the antagonist is chosen in such a way that habituation- or addiction-promoting effects and side effects of the agonist are reduced or abolished, without (substantially) affecting the analgesic effect of the agonist. According to the
25 invention, development of habituation and addiction as well as obstipation and breath depression are to be considered as side effects of analgesically effective opioid agonists.

Even though this might not be expressly stated, the term "agonist" or "antagonist"
30 always comprises pharmaceutical acceptable and equally acting derivatives, salts and

- 28 -

the like. If, for example, oxycodone or naloxone is mentioned, this also comprises, besides the free base, their hydrochloride, sulfate, bisulfate, ttrate, nitrate, citrate, bittrate, phosphate, malate, maleate, hydrobromide, hydrojodide, fumarate, succinate and the like.

5

According to the invention, agonists and antagonists are formulated in a way that they are released from the resulting pharmaceutical preparation in a sustained, independent and invariant manner. This does not mean that the antagonist is in excess compared to the agonist. On the contrary, it is preferred that in formulations comprising an agonist/antagonist combination, that show a release profile in accordance with the invention, the agonist is in excess compared to the antagonist.

10

Preparations produced according to the invention can be applied orally, nasally, rectally and/or by inhalation for use in pain therapy. According to the invention, parenteral application is not envisaged. Especially preferred is a formulation for oral application.

15

Formulations in accordance with the invention may be produced by embedding the active compound into the matrix by e.g. melting, spray-freezing, spray-drying, granulating, direct tableting and/or extrusion.

20

Pharmaceutical preparations or preliminary stages thereof which are in accordance with the invention can be produced by build-up or break-down granulation. A preferred embodiment is the production by spray granulation with subsequent drying of the granules. Another preferred embodiment is the production of granules by build-up granulation in a drum or on a granulating disk. The granules may then be pressed into e.g. tablets using appropriate additional substances and procedures.

25

The person skilled in the art is familiar with granulating technology as applied to pharmaceutical technology. The embodiment examples (see below) disclose specific

30

- 29 -

embodiments of the invention. However, it is well within the scope of the person skilled in the art to adapt the parameters of the process in order to achieve specific purposes.

5 The pharmaceutical formulations in accordance with the invention or precursors thereof may be advantageously produced by extrusion (instead of granulation), since several working steps (such as the drying of the granulates during spray-granulation) may be omitted, so that formulations in accordance with the invention may be produced efficiently and with less cost.

10

As production of formulations in accordance with the invention by extrusion is a continuous process, several working steps can be omitted (in comparison to other production methods, such as spray-granulation), leading to more efficient production of the formulations in accordance with the invention.

15

For production of formulations in accordance with the invention by extrusion Surelease®

20 E-7-7050, which comprises dibutylsebacat as plasticizer and additional other components may be omitted and ethylcellulose may be directly used, resulting in a cheaper and more efficient production process.

Production of pharmaceutical preparations or preliminary stages thereof, which are in accordance with the invention, by extrusion technology is especially advantageous.

25 In one preferred embodiment, pharmaceutical preparations or preliminary stages thereof are produced by melt extrusion with co- or counter-rotating extruders comprising two screws. Another preferred embodiment is the production by means of extrusion, with extruders comprising one or more screws. These extruders may also comprise kneading elements.

30

- 30 -

Extrusion is also a well-established production process in pharmaceutical technology and is well known to the person skilled in the art. The person skilled in the art is well aware that during the extrusion process, various parameters, such as the feeding rate, the screw speed, the heating temperature of the different extruder zones (if
5 available), the water content, etc. may be varied in order to produce products of the desired characteristics. The Example section provides for numerous examples of preparations according to the invention that have been produced by extrusion.

The aforementioned parameters will depend on the specific type of extruder used.
10 For production of formulations in accordance with the invention, extrusion may be performed with one or multiple screw extruders which may be counter-rotating or co-rotating screws. The feeding rate of the components is dependent on the specific extruder type.

15 The aforementioned parameters will depend on the specific type of extruder used. During extrusion the temperature of the heating zones, in which the components of the inventive formulation melt, may be between 40 to 120 °C, preferably between 50 to 100 °C, more preferably between 50 to 90 °C, even more preferably between 50 to 70 °C and most preferably between 50 to 65° C, particularly if counter-rotating twin
20 screw extruders (such as a Leistritz Micro 18 GGL) are used. The person skilled in the art is well aware that not every heating zone has to be heated. Particularly behind the feeder where the components are mixed, cooling at around 25 °C may be necessary. The screw speed may vary between 100 to 500 revolutions per minute (rpm), preferably between 100 to 250 rpm, more preferably between 100 to 200 rpm
25 and most preferably around 150 rpm, particularly if counter-rotating twin screw extruders (such as a Leistritz Micro 18 GGL) are used. The geometry and the diameter of the nozzle may be selected as required. The diameter of the nozzle of commonly used extruders typically is between 1 to 10 mm, preferably between 2 to 8 mm and most preferably between 3 to 5 mm. The different extruders may differ with
30 respect to their set up and comprise e.g. kneading elements. The ratio of length

- 31 -

versus diameter of the screw of extruders that may be used for production of inventive preparations is typically around 40:1.

Typical screw profiles which may be used in the production of formulations according to the invention by extrusion are shown in Figures 1A and 1B. Extrusion procedures for the production of pharmaceutical preparations which show a sustained release are well known to the person skilled in the art.

In a preferred embodiment, a counter-rotating twin-screw extruder is used for the production of formulations in accordance with the invention. This may be e.g. an extruder of the type Micro 18 GGL (Leistritz AG, Nürnberg, Germany). For this preferred embodiment the extruder has no kneading elements (see also Figure 1A). The feeding rate of the components used for the production of the formulation in accordance with the invention is between 1-3 kg/h, preferably between 1-2 kg/h. Particularly preferred is a feeding rate of 1.5 kg/h. The temperature of the heating zones is between 40°-120°C, 50°-100°C, preferably 50°-90°C, more preferably 50°-70°C. Particularly preferred are 50°-65°C. The extruder provides for 10 heating zones. In the first heating zone the components are generally cooled around 25°C. The temperature in the other heating zones will then preferably be around 50°-65°C and may vary for every heating zone. The screw speed will be between 1-500 rpm, preferably between 1-250 rpm, more preferably between 120-200 rpm and even more preferably around 150 rpm. The diameter of the nozzle will be between 1-10 mm, preferably between 2-8 mm, or between 3-5 mm. In a particularly preferred embodiment of the invention, the diameter of the nozzle is approximately 3 mm.

Generally, the temperatures of the heating zones have to be selected such that no temperatures develop that may destroy the pharmaceutically active compounds. The feeding rate und screw speed will be selected such that the pharmaceutically active compounds are released from the preparations produced by extrusion in a sustained, independent and invariant manner and are storage stable in the matrix. If e.g. the

- 32 -

feeding rate is increased, the screw speed may have to be increased correspondingly to ensure the same retardation.

5 The person skilled in the art knows that all the aforementioned parameters depend on the specific production conditions (extruder type, screw geometry, number of components etc.) and may have to be adapted such that the preparations produced by extrusion provide for a sustained, independent and invariant release as well as for the afore-mentioned storage stability. The person skilled in the art knows how to properly adjust the aforementioned parameters

10

The person skilled in the art can infer from the Examples (see below) that by changing the parameters during extrusion and by changing the composition with respect to the compounds that are substantially responsible for the release behaviour of the preparations, preparations with different release profiles may be obtained.

15 Thus, the present invention allows to first produce a preparation with a desired release profile for oxycodone and naloxone or naloxone alone by e.g. varying the amount of fatty alcohols or the matrix-forming polymer ethylcellulose as well as production parameters such as temperature, screw speed (during extrusion) or pressure power during tablet production.

20

Once a preparation with the desired release profile has been obtained, the inventive preparations according to the invention allow the person skilled in the art to change the amounts of the preparations with respect to the active compounds as outlined above. Preparations comprising different amounts of the active compounds but of
25 otherwise substantially equal composition, however, will then provide for the features of sustained, invariant and independent release.

The Example section therefore discloses numerous examples showing that preparations with different release profiles may be obtained by changing the amount
30 of e.g. ethylcellulose. Other examples show that once a preparation has been

established with desired release profiles, the change in the amount of naloxone will not influence the release behaviour of such preparations if the difference in the amount of the active compound is replaced by pharmaceutically inert excipients such as lactose.

5

The production of formulations in accordance with the invention by extrusion is preferred with the formulations comprising opioid analgesics and opioid antagonists as active compounds. Particularly preferred is the production of formulations in accordance with the invention that comprise oxycodone and naloxone, wherein the preferred weight ratios of agonist to antagonist are within a weight ratio ranging from maximal 25:1, preferably of 20:1, 15:1, 10:1, 5:1, 2:1 and 1:1.

10

A preferred embodiment of the invention refers to a preparation that comprises the inventive matrix and naloxone as the pharmaceutically active compound. Such preparations may be advantageously used for a variety of different indications.

15

Preparations according to the invention comprising an opioid antagonist such as naloxone as the pharmaceutically active compound may e.g. be used for complete or partial treatment of opioid-induced side effects. Such side effects may comprise dizziness, breath depression, opioid-abuse, development of tolerance and addiction and particularly obstipation.

20

Preparations according to the invention which comprise naloxone as a pharmaceutically active compound preferably are used for the treatment of opioid-induced obstipation. Almost 90 % of patients under opioid treatment show signs of obstipation which may be responsible for other additional ailments such as discomfort, tension and pain in the abdomen, nausea and emesis, anorexia, haemorrhoids, anal fissures, fecal incontinence, paradoxical diarrhoea, urine retention, intestinal pseudo obstruction, and decubitus of the colon which may lead to

25

- 34 -

perforation (Neuenschander et. al. (2002), Palliativmedizin auf einen Blick, Schweizerische Krebsliga).

So far opioid-induced obstipation has been treated by the application of laxatives.

- 5 However, application of typical laxatives does not allow for the simultaneous treatment of other opioid-induced side effects .

The advantage of the use of inventive preparations comprising naloxone is that the inventive preparations allow for a sustained release of the antagonist naloxone. If e.g.
10 patients in pain are treated simultaneously with opioid analgesics, application of such preparations comprising naloxone will allow for a long term treatment of opioid-induced side effects including obstipation. Particularly, the application of naloxone as a sustained release formulation should allow for an efficient treatment of opioid-induced obstipation. At the same time it is ensured that there is no tolerance
15 development towards opioid analgesics if applied simultaneously. Moreover, the use of naloxone does not lead to any disturbances in the water and electrolyte metabolism and does not induce colon irritation.

The provision of a sustained release formulation comprising naloxone as the only
20 pharmaceutical active agent compound also has the advantage that patients that are treated with opioid analgesics may receive a dosis of naloxone which is sufficient to counteract the opioid-induced side effects without leading to a significant reduce of analgesia. With inventive preparations being available which comprise different amounts of naloxone, one has the possibility to specifically treat patients in need of
25 pain treatment that receive different amounts of opioid agonists or are treated with different opioid agonists

Yet another preferred embodiment of the invention relates to the use of inventive preparations comprising naloxone for treatment of opioid-induced pruritus. Opioid-

- 35 -

induced pruritus is one of the side effects that is experienced by the patients as extremely unpleasant.

In another embodiment of the invention, preparations comprising naloxone may also
5 be used for treatment of idiopathic syndromes such as idiopathic pruritus or pruritus
due to cholestasia and/or renal dysfunction. These preparations may also be used for
the treatment of chronic idiopathic obstipation or irritable bowel syndrome. Thus,
preparations in accordance with the invention comprising naloxone as a
pharmaceutically active compound may be used for a multitude of therapeutic
10 indications and purposes which may be either opioid-induced or not. As the inventive
preparations provide for a sustained and reproducibly invariant release behaviour,
they allow for an efficient treatment of the aforementioned syndromes.

In a preferred embodiment preparations in accordance with the invention comprising
15 naloxone as the active compound release 30% to 60 %, preferably 35% to 55 %, more
preferably 40% to 50 % and even more preferably 40% to 45 % or 45% to
50 % of naloxone after 90 minutes. In another preferred embodiment of the
invention, preparations comprising naloxone release approximately 40 %, approximately
45 % or approximately 50 % of the active compound after 90 minutes.

20

In another preferred embodiment preparations in accordance with the invention
comprising naloxone release 30% to 70 %, preferably 35% to 65 % and more
preferably between 40% to 60 % of naloxone after 120 minutes. In yet another
embodiment of the invention, preparations comprising naloxone release preferably
25 between 35% to 40%, 40% to 45 % and 45% to 50 % of naloxone after 120 minutes.
In another preferred embodiment of the invention the preparations comprising
naloxone release approximately 35%, approximately 40%, approximately 45 %, approximately
50% or approximately 55% of naloxone after 120 minutes.

- 36 -

In another preferred embodiment preparations in accordance with the invention comprising naloxone release 55% - 90 %, preferably 60% to 80 %, more preferably 65% to 75 % and even more preferably 65% to 70 % or 70% to 75 % of naloxone after 420 minutes. In yet another preferred embodiment of the invention, preparations
5 comprising naloxone release approximately 65%, approximately 70% or approximately 75 % of naloxone after 420 minutes.

In another preferred embodiment preparations in accordance with the invention comprising naloxone release 60% to 90 %, preferably 65% to 85 %, more preferably
10 70% to 80 % and even more preferably 75% to 80 % of naloxone after 600 minutes. In yet another preferred embodiment of the invention, preparations comprising naloxone release approximately 75%, approximately 80% or approximately 85 % of naloxone after 600 minutes.

15 Examples that display highly advantageous embodiments of the invention are set out below. Examples are also given showing that formulations which are in accordance with the invention differ mainly in their structure from formulations with a sustained release which has been produced by using commonly used scaffold-forming polymers. Only the formulations produced in accordance with the invention provide
20 for a sustained, invariant and, if several compounds are present, independent release of the active compounds with the formulation being storage stable. The examples are not to be interpreted as limiting the possible embodiments of the invention.

- 37 -

Example 1 – Production of tablets with different oxycodone/naloxone amounts in a non-swellable diffusion matrix by spray granulation:

The following amounts of the listed components were used for the production of
5 oxycodone/naloxone tablets according to the invention.

Preparation (designation)	Oxy/Nal-0	Oxy/Nal-5	Oxy/Nal-10
oxycodone HCl	20.0 mg	20.0 mg	20.0 mg
naloxone HCl	-	5.0 mg	10.0 mg
Lactose Flow Lac 100	59.25 mg	54.25 mg	49.25 mg
Povidone 30	5.0 mg	5.0 mg	5.0 mg
Surelease®	10.0 mg solid material	10.0 mg solid material	10.0 mg solid material
Stearyl alcohol	25.0 mg	25.0 mg	25.0 mg
Talcum	2.5 mg	2.5 mg	2.5 mg
Mg-Stearate	1.25 mg	1.25 mg	1.25 mg

The Surelease® E-7-7050 polymer mixture used had the following composition.

Surelease®
Ethylcellulose 20 cps
Dibutylsebacate
Ammoniumhydroxide
Oleic acid
Siliciumdioxide
Water

10

For the production of tablets oxycodone HCl, naloxone HCl, Povidone 30 and Lactose Flow Lac 100 were mixed in a tumbling mixer (Bohle) and subsequently spray-granulated with Surelease® E-7-7050 in a fluidized bath granulating device (GPCG3). The material was sieved over a Comill 1.4 mm sieve. An additional

15 granulation step was carried out with melted fatty alcohol in a high-shear mixer

(Collette). All tablet cores produced by this approach had a weight of 123 mg, based on dry substance.

5 **Example 2 – Production of tablets with oxycodone and naloxone in a non-swellable diffusion matrix by extrusion:**

The following amounts of the listed components were used for the production of the oxycodone/naloxone tablets according to the invention.

10

Preparation (designation)	Oxy/Nal-Extr
oxycodone HCl	20 mg
naloxone HCl	10 mg
Kollidon 30	6 mg
Lactose Flow Lac 100	49.25 mg
Ethylcellulose 45 cpi	10 mg
Stearyl alcohol	24 mg
Talcum	2.5 mg
Mg-Stearate	1,25 mg

The listed amounts of oxycodone HCl, naloxone HCl, ethylcellulose 45 cpi, Povidone 30, stearyl alcohol and Lactose Flow Lac 100 were mixed in a tumbling mixer (Bohle). This mixture was subsequently extruded with a counter-rotating twin
15 screw extruder of the type Micro 18 GGL (Leistritz AG, Nürnberg, Germany). The temperature of heating zone 1 was 25°C, of heating zone 2, 50°C, of heating zones 3 to 5, 60°C, of heating zones 6 to 8, 55°C, of heating zone 9, 60°C and of heating zone 10, 65°C. The screw rotating speed was 150 revolutions per minute (rpm), the resulting melt temperature was 87°C, the feed rate was 1.5 kg/h and the diameter of
20 the nozzle opening was 3 mm. The extruded material was sieved with a Frewitt 0.68 x 1.00 mm sieve. The grinded extrudate was then mixed with talcum and magnesium stearate that had been added over a 1 mm hand sieve and was subsequently pressed into tablets. The extruder has a screw geometry, as shown in Fig. 1A.

In comparison to the oxycodone/naloxone tablets which also have the Surelease®-based non-swellable diffusion matrix produced by spray granulation (see Example 1), extruded preparations comprise less components.

5

Example 3 – Release profile of the oxycodone/naloxone tablets from Example 1:

The release of the active compounds was measured over a time period of 12 hours, applying the Basket Method according to USP at pH 1.2 using HPLC. Tablets Ox/Nal-0, Ox/Nal-5 and Ox/Nal-10 were tested.

One recognizes from Fig. 2 and the values listed in the Table that in the case of a non-swellable diffusion matrix based on Surelease®, the release rates of different oxycodone amounts, independent of the naloxone amount, remain equal (invariant). Correspondingly, invariant release profiles are observed for naloxone at different oxycodone amounts.

Time (min)	Ox/Nal-0	Ox/Nal-5-O	Ox/Nal-5-N	Ox/Nal-10-O	Ox/Nal-10-N
	Oxy	Oxy	Nal	Oxy	Nal
0	0	0	0	0	0
15	26.1	24.9	23.5	22.8	24.1
120	62.1	63	61	57.5	60.2
420	91.7	94.5	91.9	89.4	93.5
720	98.1	99.6	96.6	95.7	100.6

The release values refer to oxycodone or naloxone (line 2) and are given as percentages. The mean value for the release of naloxone at e. g. 420 min is 92,7%. The maximal deviation at 420 min is 1%. Oxy and Nal stand for oxycodone and naloxone and indicate the active compound which has been measured.

20

- 40 -

Example 4 – Release profile of oxycodone/naloxone tablets from Example 2 at different pH-values:

- 5 The release of active compounds from the tablets was measured over a time period of 12 hours at pH 1.2 or for 1 hour at 1.2 and subsequently for 11 hours at pH 6.5. Release rates were determined by the basket method according to USP using HPLC.

The following release rates were measured for 12 hours at pH 1.2:

10

Time (min)	Oxy/Nal-Extr-1,2-O	Oxy/Nal-Extr-1,2-N
	Oxy	Nal
0	0	0
15	24.1	24.0
120	62.9	63.5
420	92.9	93.9
720	96.9	98.1

The following release rates were measured for 1 hour at pH 1.2 and 11 hours at pH 6.5:

Time (min)	Oxy/Nal-Extr-6,5-O	Oxy/Nal-Extr-6,5-N
	Oxy	Nal
0	0	0
60	48.1	49.2
120	65.0	64.7
240	83.3	81.8
420	94.1	92.3

15

The release rates refer to oxycodone and naloxone (line 2) and are given as percentages. Oxy and Nal stand for oxycodone and naloxone and indicate the active compound measured.

The comparison of the values given in the Tables of Example 4 and the Table of Example 3 make clear that independent of the production process, active compounds are released in equal amounts from the preparations. For example, 89.4% of oxycodone is released from spray-granulated tablets (Ox/Nal-10-tablets, see Example 3) at 420 minutes, while 92.9% is released from extruded tablets (Oxy/Nal-Extr.-1.2-O, Example 4) at 420 minutes. The release of oxycodone from extruded tablets thus deviates by 1.1% from the mean value of the release of oxycodone from spray-granulated tablets (91.9% at 420 minutes). 93.5% of naloxone is released from spray-granulated tablets (Ox/Nal-10-tablets, see Example 3) at 420 minutes, while 93.9% is released from extruded tablets (Oxy/Nal-Extr.-1.2-O, Example 4) at 420 minutes. The release of naloxone from extruded tablets thus deviates by 1.3% from the mean value of the release of naloxone from spray-granulated tablets (92.7% at 420 minutes).

Moreover, one can infer from a comparison of the values of the Tables of Example 4 and from Figures 3A and 3B that independent of the pH value at which the release rates have been measured the release of oxycodone and naloxone remain equal and invariant.

20

Example 5 – Comparative example: release behaviour of Valoron® tablets:

The release of the active substances from tablets was monitored over a time period of 7 hours. Valoron® tablets with 50 mg tilidine and 4 mg naloxone (Ti/Nal-50/4) or 100 mg tilidine and 8 mg naloxone (Ti/Nal-100/8) or 150 mg tilidine and 12 mg naloxone (Ti/Nal-150/12) were tested by the Basket Method according to USP for 1h at pH 1.2 and then for additional 6h at pH 6.5 using HPLC .

One recognizes from Figures 4A and 4B and the values listed in the Table that in case of a swellable (and possibly erosive) diffusion matrix with relevant amounts of

HPMC, the release of different amounts of tilidine varies significantly and is not invariant for different amounts of naloxone. This applies in turn to naloxone. This means that for this pH the release of the active compounds is not independent of each other.

5

Time (min)	Ti/Nal- 50/4-T	Ti/Nal- 50/4-N	Ti/Nal- 100/8-T	Ti/Nal- 100/8-N	Ti/Nal- 150/12-T	Ti/Nal- 150/12-N
	Til	Nal	Til	Nal	Til	Nal
0	0	0	0	0	0	0
60	37.2	27.6	33.9	27.3	29.9	23.3
120	47.6	31.7	46.5	33.4	41.5	28.5
180	54.7	37.4	55	41.2	48.2	35
240	59.7	44	68.2	59.5	54.5	40.1
300	65.2	50.6	82.6	72.9	60.5	47.5
360	70.3	58	85.7	82.7	67.2	56.4
420	74.2	60.8	93.1	90.9	84.9	78.9

The release values refer to tilidine or naloxone (line 2) and are given as percentages.

The mean value for the release of naloxone at e. g. 420 min is 78,87%. The maximal deviation at 420 min is 20,4%. Til und Nal stand for tilidine and naloxone and

10 indicate the active compound tested.

Example 6 – Structure comparison of tablets of Examples 1 and 2 with Valoron® N tablets by electron microscopy.

15

For electron microscopy tablets were used that comprised 20 mg oxycodone and 10 mg naloxone and were produced either by spray granulation according to Example 1 (Ox/Nal-10) or by extrusion according to Example 2 (Oxy/Nal-Extr). Additionally, a Valoron® N tablet with 100 mg Tilidin and 8 mg Naloxone was used. Figures 5A and 5B show different magnifications of scanning electron microscopy pictures of a Ox/Nal-10-tablet with a formulation according to the invention which was produced by spray granulation. Figures 6A and 6B show different magnifications of scanning

20

- 43 -

electron microscopy pictures of a Oxy/Nal-Extr-tablets with a formulation according to the invention, which was produced by extrusion. Figures 7A and 7B show scanning electron microscopy pictures of the Valoron® N-tablet.

- 5 From a comparison of the figures one can clearly see that tablets with a formulation according to the invention have a surface which is substantially finer and more homogeneously structured and which shows fewer cracks than the Valoron® tablet, regardless of whether the tablets have been produced by spray granulation or extrusion. The structural difference is possibly the reason for the different release
10 behaviours of the different preparations.

Example 7 - Production of tablets comprising different amounts of naloxone and different matrices by spray granulation.

15

The following amounts of the listed components were used for the production of naloxone tablets:

Preparation (designation)	Nal-5-Eud	Nal-5-Sure	Nal-10-Sure
naloxone HCl	5.0 mg	5.0 mg	10.0 mg
Lactose Flow Lac 100	74.25 mg	74.25 mg	69.25 mg
Povidone 30	5.0 mg	5.0 mg	5.0 mg
EUDRAGIT® RS 30D	10 mg solid material	---	---
Surelease®	---	10 mg solid material	10 mg solid material
Triacetin	2.0 mg	---	---
Stearyl alcohol	25.0 mg	25.0 mg	25.0 mg
Talcum	2.5 mg	2.5 mg	2.5 mg
Mg-Stearate	1.25 mg	1.25 mg	1.25 mg

- EUDRAGIT® RS 30 D can be purchased from Röhm GmbH, Darmstadt. Surelease®
20 can be purchased from Colorcon Ltd., Idstein.

- 44 -

EUDRAGIT® RS 30 D or Surelease®-Polymer mixtures of the following compositions were used:

EUDRAGIT® RS 30 D	Surelease®
Ammoniomethacrylate copolymer B	Ethylcellulose 20 cps
Sorbic acid	Dibutylsebacate
Natriumhydroxide	Ammoniumhydroxide
Water	Oleic acid
	Siliciumdioxide
	Water

5

For the production of tablets, naloxone HCl, Povidone 30 and Lactose Flow Lac 100 were mixed in a tumbling mixer (Bohle) and subsequently spray-granulated with EUDRAGIT® RS 30 D or Surelease® in a fluidized bath granulating device (GPCG3). An additional granulation step was carried out with melted fat alcohol in a high-shear mixer (Collette). All tablet cores produced by this approach had a weight of 125 mg, referred to the dry substance.

10

Example 8 – Production of tablets with naloxone in a non-swellable diffusion matrix by extrusion:

15

The following amounts of the listed components were used for the production of naloxone tablets according to the invention.

- 45 -

Preparation (designation)	Nal-Extr
naloxone HCl	10 mg
Lactose Flow Lac 100	70.25 mg
Kollidone 30	5 mg
Ethylcellulose 45 cpi	8 mg
Stearyl alcohol	26.0 mg
Talcum	2.5 mg
Mg-Stearate	1.25 mg

- The listed amounts of naloxone HCl, ethylcellulose 45 cpi, Kollidone 30, stearyl alcohol and Lactose Flow Lac 100 were mixed in a tumbling mixer (Bohle). This mixture was subsequently extruded with a counter-rotating twin screw extruder of the type Micro 18 GGL (Leistritz AG, Nürnberg, Germany). The temperature of heating zone 1 was 25°C, of heating zone 2, 50°C, of heating zones 3 to 10, 55°C. The screw rotating speed was 140 rpm, the resulting melt temperature was 65 °C, the feed rate was 1.25 kg/h and the diameter of the nozzle opening was 3 mm. The extruded material was sieved with a Frewitt 0.68 x 1.00 mm sieve. The grinded extrudate was then mixed with talcum and magnesium stearate that had been added over a 1 mm hand sieve and was subsequently pressed into tablets. The extruder has a screw geometry, as shown in Fig. 1.
- In comparison to the oxycodone/naloxone tablets which also have the Surelease®-based non-swellable diffusion matrix produced by spray granulation (see Example 7), extruded preparations comprise less components.

Example 9 – Release behaviour of naloxone tablets from Example 7

The release of the active compound was measured over a time period of 16 hours, applying the Basket Method according to USP at pH 1.2 using HPLC. Two tablets
5 (designated A and B) of Nal-5-Eud, Nal-5-Sure and Nal-10-Sure were tested.

One recognizes from Fig. 8A and 8B and the values listed in the Table that in the case of a non-swellable diffusion matrix based on Surelease®, the release rates of naloxone independent of the absolute amount reproducibly do not change and remain
10 substantially equal (invariant). This does not apply for the release of naloxone from matrix based on Eudragit®.

Time (min)	Nal-5-Eud-A	Nal-5-Eud-B	Nal-5-Sure-A	Nal-5-Sure-B	Nal-10-Sure-A	Nal-10-Sure-B
0	0	0	0	0	0	0
15	18.48	18.23	23.86	21.97	20.65	22.25
90	40.46	26.15	46.74	47.33	45.18	45.98
240	62.43	53.47	70.48	69.49	69.13	68.76
420	82.9	72.27	91.04	88.69	88.06	87.5
720	97.46	85.74	100.62	99.1	96.05	95.74
960	107.6	96.26	102.26	102.33	97.91	97.43

The release values refer to naloxone and are given as percentages. The mean value
15 for the release of naloxone in the case of e.g. Nal-Sure tablets at 90 min is 46.3%.
The maximal deviation at 90 min is 2.2%. The mean value at this time point for Nal-Eud tablets is 33.3% and the deviation is 21.5%.

Example 10 – Release behaviour of naloxone tablets from Example 8

The release of the active compound was measured for different tablets over a time period of 12 hours, applying the Basket Method according to USP at pH 1.2 using HPLC.

One recognizes from Fig. 9 and the values listed in the Table that the release of naloxone independent of the production process reproducibly does not change when tablets have been produced by extrusion.

10

Zeit (min)	Nal-Extr-A	Nal-Extr-B	Nal-Extr-C
0	0	0	0
15	15	15	14.3
120	40.7	41.9	40.1
420	72	75.2	73.6
720	90.1	92.4	91.2

The release values refer to naloxone and are given as percentages. The mean value for the release of naloxone in the case of Nal-Extr tablets at 120 min is 40.9%. The maximal deviation at 120 min is 2.4%.

15

Example 11 – Structure comparison of naloxone tablets of Examples 7 and 8.

For electron microscopy, Nal-Eud tablets according to Example 7 with 5 mg (Nal-5-Eud) as well as a Nal-Extr tablets according to Example 8.

Figures 10A and 10B show different magnifications of scanning electron microscopy pictures of a Nal-5-Eud tablet. Figures 11A and 11B show different magnifications of scanning electron microscopy pictures of a Nal-Extr tablets with a formulation in accordance with the invention.

25

- 48 -

From a comparison of the figures, one can clearly see that the formulation in accordance with the invention has a surface which is substantially finer and more homogeneously structured. Particularly, in Figures 10A and 10B naloxone blooms can be seen, but not in Figures 11A and 11B. This structural difference is possibly the reason for the different release behaviour of the different preparations.

Example 12 – Structure comparison of naloxone granulates of Examples 7 and 8.

10

For electron microscopy, granulates as they were used for production of Nal-Sure tablets according to Example 7 with 10 mg naloxone (Nal-10-Sure) and Nal-Extr tablets according to Example 8 were used.

15 Figures 12A and 12B show different magnifications of scanning electron microscopy pictures of Nal-10-Sure granulates. Figures 13A and 13B show different magnifications of scanning electron microscopy pictures of a Nal-Extr granulates with a formulation in accordance with the invention.

20 One can clearly see that independent of the production process granulates with a formulation in accordance have homogeneously structured surfaces without major cracks or blooms. Without wanting to be bound to a scientific theory it is assumed that the surface characteristics are responsible for the release behaviour of the formulations in accordance with the invention.

25

Example 13 – Storage stability of naloxone tablets depending on the matrix used.

Multiple tablets comprising either EUDRAGIT® RS 30 D or Surelease® and 5 mg
30 naloxone were produced as described in Example 1. The tablets were stored at 25° C

and 60% relative humidity. At different time points, the release behaviour was tested as described in Example 4.

As can be recognized from Figures 4A and 4B and the Tables, the release profiles of
 5 naloxone tablets having been formulated with EUDRAGIT®RS 30 D , differ already after a short time of storage. In contrast, the release profile of tablets which have been formulated with Surelease® are almost invariant, even after 15 months of storage.

Storage time (Months)	0	1	3,5
Preparation (designation)	Nal-5-Eud-0	Nal-5-Eud-1	Nal-5-Eud-3,5
Time (min)			
15	16.46	12.66	15.06
90	30.29	28.78	30.6
240	52.94	43.85	47.5
480	71.07	57.37	62.86
720	83.29	66.68	73.58
1020	91.61	73.03	80.97

10

Storage time (Months)	0	3	6	15
Preparation (designation)	Nal-5-Sure-0	Nal-5-Sure-3	Nal-5-Sure-6	Nal-5-Sure-15
Time (min)				
15	21.58	22.52	16.04	24.36
120	49.94	49.05	51.93	55.59
420	79.83	86.32	87.99	88.49
720	91.74	97.55	100.27	97.09

In the Table, the release rates are given in percentages. In each case, the release of
 15 naloxone was tested.

- 50 -

Example 14 – Production of tablets with different oxycodone/naloxone amounts in a non-swellable diffusion matrix by extrusion:

The following amounts of the listed components were used for the production of
5 oxycodone/naloxone tablets according to the invention.

Preparation (designation)	OxN20/1-Extr-A	OxN20/1-Extr-B	OxN20/1-Extr-C	OxN20/10-Extr-A
Oxycodone HCl	20 mg	20 mg	20 mg	20 mg
Naloxone HCl	1 mg	1 mg	1 mg	10 mg
Lactose Flow Lac 100	58.25 mg	58.25 mg	58.25 mg	49.25 mg
Kollidon® 30	6 mg	6 mg	6 mg	6 mg
Ethylcellulose	10 mg	10 mg	10 mg	10 mg
Stearly alcohol	24 mg	24 mg	24 mg	24 mg
Talcum	1.25 mg	1.25 mg	1.25 mg	1.25 mg
Mg-Stearate	2.5 mg	2.5 mg	2.5 mg	2.5 mg

Extrusion was performed as described above (Example 2) with the following
10 parameters:

OxN20/1-Extr-A: temperature: 55-63 °C
 rpm (screw): 150 rpm
 feeding rate: 1.5 kg/h

15

OxN20/1-Extr-B: temperature: 55-63 °C
 rpm (screw): 155 rpm
 feeding rate: 1.5 kg/h

20

- 51 -

	OxN20/1-Extr-C:	temperature:	55-63 °C
		rpm (screw):	1505rpm
		feeding rate:	1.5 kg/h
5	OxN20/10-Extr-A:	temperature:	55-63 °C
		rpm (screw):	160 rpm
		feeding rate:	1.75 kg/h

10 Tablet production was performed with a common tableting device with the following parameters:

	OxN20/1-Extr-A:	rpm:	40 rpm
		Pressure power:	9 kN
15	OxN20/1-Extr-B:	rpm:	42 rpm
		Pressure power:	8.9 kN
	OxN20/1-Extr-C:	rpm:	36 rpm
		Pressure power:	9 kN
20	OxN20/10-Extr-A:	rpm:	36 rpm
		Pressure power:	7.5 kN

25 The release of the active compounds was measured over a time period of 12 hours, applying the Basket Method according to USP at pH 1.2 using HPLC. Tablets OxN20/1-Extr-A, OxN20/1-Extr-B, OxN20/1-Extr-C and OxN20/10-Extr-A were tested.

30 One recognizes from the values listed in the Table that in the case of a non-swellable diffusion matrix based on ethylcellulose, the release rates of different naloxone

amounts, independent of the oxycodone amount, remain substantially equal. Correspondingly, the preparations provide for an independent and invariant release of the active compounds.

Time (min)	OxN20/1- Extr-A		OxN20/1- Extr-B		OxN20/1- Extr-C		OxN20/10- Extr-A	
	Oxy	Nal	Oxy	Nal	Oxy	Nal	Oxy	Nal
0	0	0	0	0	0	0	0	0
15	21.2	25.8	21.7	21.1	19.7	19.3	23.3	24.3
120	56.6	53.8	58.8	57.3	57.7	56.2	64.5	66.9
420	87.2	84.5	94.2	92.6	93.7	91.5	92.7	96.3
720	99.7	96.8	100.1	98	100.6	97.5	93.6	97.4

5

The release values refer to oxycodone or naloxone (line 2) and are given as percentages. The mean value for the release of naloxone at e. g. 420 min is 92.3%. The maximal deviation at 420 min is 7.4%. Oxy and Nal stand for oxycodone and naloxone and indicate the active compound which has been measured.

10

Thus, once a preparation with the desired release profile has been developed, one can change the amount of the active compounds without significantly changing the release profiles of the active compounds. The preparations comprising different amounts of the active compounds still provide for a sustained, independent an

15 invariant release of the active compounds.

Example 15 – Production of tablets with oxycodone/naloxone in a non-swellable diffusion matrix by extrusion:

20

In the following example it is set out that using formulations according to the present invention, preparations comprising oxycodone and naloxone with particular release behaviours may be obtained.

The following amounts of the listed components were used for the production of oxycodone/naloxone tablets according to the invention.

Preparation (designation)	OxN20/1- Extr-D	OxN20/1- Extr-E	OxN20/10- Extr-B	OxN20/10- Extr-C	OxN20/10- Extr-D	OxN20/10- Extr-E
oxycodone HCl	20 mg	20 mg	20 mg	20 mg	20 mg	20 mg
naloxone HCl	1 mg	1 mg	10 mg	10 mg	10 mg	10 mg
Lactose Flow Lac 100	56.25 mg	56.25 mg	54.25 mg	65.25 mg	60.25 mg	55.25
Kollidon® 30	7 mg	6 mg	6 mg	7.25 mg	7.25 mg	7.25 mg
Ethylcellulose	11 mg	12 mg	10 mg	12 mg	12 mg	12 mg
Stearyl alcohol	24 mg	24 mg	24 mg	28.75 mg	28.75 mg	28.75 mg
Talcum	1.25 mg	1.25 mg	1.25 mg	1.25 mg	1.25 mg	1.25 mg
Mg-Stearate	2.5 mg	2.5 mg	2.5 mg	2.5 mg	2.5 mg	2.5 mg

5 Extrusion was performed as described above (Example 2) with the following parameters:

10 OxN20/1-Extr-D: temperature: 55-63 °C
rpm (screw): 150 rpm
feeding rate: 1.5 kg/h

15 OxN20/1-Extr-E: temperature: 55-63 °C
rpm (screw): 150 rpm
feeding rate: 1.5 kg/h

OxN20/10-Extr-B: temperature: 55-63 °C
rpm (screw): 160 rpm
feeding rate: 1.75 kg/h

20 OxN20/10-Extr-C: temperature: 55-63 °C
rpm (screw): 160 rpm
feeding rate: 1.75 kg/h

- 54 -

	OxN20/10-Extr-D:	temperature:	55-63 °C
		rpm (screw):	150 rpm
		feeding rate:	1.5 kg/h
5	OxN20/10-Extr-E:	temperature:	55-63 °C
		rpm (screw):	150 rpm
		feeding rate:	1.5 kg/h
10	Tablet production was performed with a common tableting device with the following parameters:		
	OxN20/1-Extr-D:	rpm:	39 rpm
		Pressure power:	11 kN
15	OxN20/1-Extr-E:	rpm:	39 rpm
		Pressure power:	10.5 kN
	OxN20/10-Extr-B:	rpm:	36 rpm
20		Pressure power:	9.5 kN
	OxN20/10-Extr-C:	rpm:	36 rpm
		Pressure power:	7.8 kN
25	OxN20/10-Extr-D:	rpm:	39 rpm
		Pressure power:	9 kN
	OxN20/10-Extr-E:	rpm:	39 rpm
		Pressure power:	7.5 kN
30			

- 55 -

The release of the active compounds was measured over a time period of 12 hours, applying the Basket Method according to USP at pH 1.2 using HPLC. Tablets OxN20/1-Extr-D, OxN20/1-Extr-E, OxN20/10-Extr-B, OxN20/10-Extr-C,

5 OxN20/10-Extr-D and OxN20/10-Extr-E were tested.

Time (min)	OxN20/1- Extr-D		OxN20/1- Extr-E		OxN20/10- Extr-B		OxN20/10- Extr-C		OxN20/10- Extr-D		OxN20/10- Extr-E	
	Oxy	Nal	Oxy	Nal	Oxy	Nal	Oxy	Nal	Oxy	Nal	Oxy	Nal
0	0	0	0	0	0	0	0	0	0	0	0	0
15	16.6	16.2	17.4	17.2	26.1	26.8	21.8	21.9	18.5	18.2	18.4	18.2
120	47.6	46.9	49.6	49.7	71.1	73.0	61.2	61.8	52.8	52.8	53.3	53.3
420	82.7	84.5	84.6	85.7	94.3	96.6	93.2	94.7	86.3	86.3	87.2	88.2
720	95	97	95.2	95.8	94.9	97.9	96.4	97.9	94.8	94.8	95.7	96.5

The release values refer to oxycodone or naloxone (line 2) and are given as percentages. Oxy and Nal stand for oxycodone and naloxone and indicate the active
10 compound which has been measured.

The example shows that preparations with particular release profiles may be produced if ethylcellulose and fatty alcohols are used as the matrix-components that essentially influence the release characteristics of the preparations. Once a
15 preparation with desired release characteristics has been obtained the amount of the active compounds may be changed. The preparations will still provide for a sustained, independent and invariant release behaviour (see example 14).

20 Example 16 – Production of tablets with naloxone in a non-swellable diffusion matrix by extrusion:

The following amounts of the listed components were used for the production of naloxone tablets according to the invention.

25

Preparation (designation)	N10-Extr- 1	N10-Extr- 2	N10-Extr- 3	N10-Extr- 4	N10-Extr- 5	N10-Extr- 6
Naloxone HCl	10 mg	10 mg	10 mg	10 mg	10 mg	10mg
Lactose Flow Lac 100	69.25 mg	69.25 mg	69.25 mg	69.25 mg	69.25 mg	69.25 mg
Povidone 30	5.0 mg	5.0 mg	5.0 mg	5.0 mg	5.0 mg	5.0 mg
Ethylcellulose	10 mg	10 mg	10 mg	10 mg	10 mg	10 mg
Stearyl alcohol	25 mg	25 mg	25 mg	25 mg	25 mg	25 mg
Talcum	1.25 mg	1.25 mg	1.25 mg	1.25 mg	1.25 mg	1.25 mg
Mg-Stearate	2.5 mg	2.5 mg	2.5 mg	2.5 mg	2.5 mg	2.5 mg

Extrusion was performed as described above with the following parameters:

5	N10-Extr-1:	temperature:	55-63 °C
		rpm (screw):	120 rpm
		feeding rate:	1.5 kg/h

10	N10-Extr-2:	temperature:	55-63 °C
		rpm (screw):	140 rpm
		feeding rate:	1.5 kg/h

N10-Extr-3:	temperature:	55-63 °C
	rpm (screw):	160 rpm
	feeding rate:	1.75 kg/h

N10-Extr-4	:	temperature:	55 °C
		rpm (screw):	120 rpm
		feeding rate:	1.75 kg/h

20	N10-Extr-5:	temperature:	55-55 °C
		rpm (screw):	140 rpm
		feeding rate:	1.5 kg/h

- 57 -

N10-Extr-6: temperature: 55 °C
 rpm (screw): 160 rpm
 feeding rate: 1.5 kg/h

- 5 Tablet production was performed with a common tableting device with the following parameters:

10	N10-Extr-1	rpm:	39 rpm
		Pressure power:	11.6 kN
	N10-Extr-2:	rpm:	39 rpm
		Pressure power:	12.5 kN
15	N10-Extr-3:	rpm:	39 rpm
		Pressure power:	11.6 kN
	N10-Extr-4:	rpm:	36 rpm
		Pressure power:	14.5 kN
20	N10-Extr-5:	rpm:	36 rpm
		Pressure power:	15.0 kN
	N10-Extr-6:	rpm:	36 rpm
		Pressure power:	15.0 kN
25			

The release of the active compound was measured over a time period of 12 hours, applying the Basket Method according to USP at pH 1.2 using HPLC. Tablets N10-Extr-A, N10-Extr-B, N10-Extr-C, N10-Extr-D, N10-Extr-E and N10-Extr-F were
30 tested.

- 58 -

One recognizes the values listed in the Table that, in the case of a non-swellable diffusion matrix based on ethylcellulose and a fatty alcohol, the release rates of naloxone remain substantially equal (invariant).

5

Time (min)	N10- Extr-1	N10- Extr-2	N10- Extr-3	N10- Extr-4	N10- Extr-5	N10- Extr-6
0	0	0	0	0	0	0
15	13.0	12.9	13.0	13.2	13.3	13.5
120	37.4	37.6	37.9	37.6	37.9	38.7
420	67	67.3	67.9	67.5	67.4	69.5
600	78.1	78.5	78.7	78.4	78.3	80.5

The release values refer to naloxone and are given as percentages. The mean value for the release of naloxone at e. g. 420 min is 67.8%. The maximal deviation at 420 min is 2.5%.

10

Claims

1. Storage stable pharmaceutical formulation comprising at least one pharmaceutically active compound in a diffusion matrix,
5 **characterized in that** the matrix is determined with respect to its essential release characteristics by ethylcellulose or an ethylcellulose-based polymer and at least one fatty alcohol and that the active compounds are released from the substantially non-swellable diffusion matrix in a sustained, invariant and, if several compounds are present, independent manner.
- 10 2. Pharmaceutical formulation according to claim 1,
characterized in that the fatty alcohol comprises lauryl, myristyl, stearyl, cetylstearyl, ceryl and/or cetylalcohol, preferably stearyl alcohol.
- 15 3. Pharmaceutical formulation according to claim 1 or 2,
characterized in that the formulation comprises ethylcellulose.
4. Pharmaceutical formulation according to one of the preceding claims,
20 **characterized in that** the formulation does not comprise relevant amounts of alkaline and/or water-swellable substances, particularly derivatives of acrylic acid and/or hydroxyalkylcelluloses.
5. Pharmaceutical formulation according to one of the preceding claims,
25 **characterized in that** the formulation comprises common pharmaceutical excipients, particularly fillers, lubricants, flowing agents and/or plasticizers.
6. Pharmaceutical formulation according to claim 5,
characterized in that the fillers are selected from the group comprising sugars, preferably lactose, glucose and/or saccharose, starches and hydrolysates thereof,
30 preferably micro-crystalline cellulose and/or cellactose, sugar alcohols, preferably

- 60 -

sorbitol and/or mannitol, poorly soluble calcium salts, preferably calcium hydrogenphosphate, dicalciumphosphate or tricalciumphosphate and/or povidone.

7. Pharmaceutical formulation according to claim 5,
5 **characterized in that** it comprises magnesium stearate, calcium stearate and/or calcium laureate and/or fatty acids, preferably stearic acid as lubricant.

8. Pharmaceutical formulation according to claim 5,
characterized in that it comprises highly dispersed silica, preferably Aerosil®,
10 talcum, corn starch, magnesium oxide, magnesium and/or calciumstearate as flowing agent.

9. Pharmiacetical formulation according to claim 5,
characterized in that it comprises dibutyl sebacate as plasticizer.

15
10. Pharmaceutical preparation according to one of the preceding claims,
characterized in that the formulation can be stored over a period of at least two years under standard conditions (60% relative humidity, 25°C) in accordance with admission guidelines.

20
11. Pharmaceutical preparation according to one of the preceding claims,
characterized in that it comprises opioid analgesics as the pharmaceutically active compounds, preferably morphine, oxycodone, hydromorphone, propoxyphene, nicomorphine, dihydrocodeine, diamorphine, papaveretum, codeine, ethylmorphine,
25 phenylpiperidine and/or derivatives thereof, methadone, dextropropoxyphene, buprenorphine, pentazocin, tilidine, tramadol and hydrocodone and/or opioid antagonists, preferably naltrexone, naloxone, nalmeferine, nalorphine, nalbuphin, naloxonazine, methylnaltrexone, ketylcyclazocine, norbinaltorphimine, naltrindol, 6-β-naloxol and/or 6-β-naltrexol.

30

- 61 -

12. Pharmaceutical formulation according to claim 11,
characterized in that the opioid analgesic and/or the antagonist are present in the
form of their pharmaceutically acceptable and equally active derivatives, such as the
free base, salts and the like, preferably as the hydrochloride, sulfate, bisulfate, ttrate,
5 nitrate, citrate, bittrate, phosphate, malate, maleate, hydrobromide, hydroiodide,
fumarate or succinate.

13. Pharmaceutical formulation according to claim 11 or 12,
characterized in that the formulation comprises at least two active compounds
10 which are oxycodone and naloxone, and wherein oxycodone is present in an amount
ranging from 10 to 150 mg, preferably from 10 to 80 mg and naloxone is present in
an amount ranging from 1 to 50 mg per unit dosage.

14. Pharmaceutical formulation according to claim 13,
15 **characterized in that** it comprises oxycodone and naloxone in a weight ratio
ranging from maximal 25:1, preferably maximal 20:1, 15:1 and more preferably from
5:1, 4:1, 3:1, 2:1 and 1:1.

15. Pharmaceutical formulation according to claim 11 or 12,
20 **characterized in that** it contains oxycodone and naloxone with oxycodone being
present in an amount ranging from 10 to 150 mg, preferably from 10 to 80 mg and
naloxone being present in an amount ranging from 1 to 50 mg.

16. Pharmaceutical preparation according to one of the preceding claims,
25 **characterized in that** the formulation is a tablet, preferably a multi-layered tablet, a
capsule, a dragée, a granulate and/or a powder.

17. Pharmaceutical formulation according to claim 16,
characterized in that the pharmaceutical preparation is suitable for oral, nasal and/or
30 rectal application.

- 62 -

18. Pharmaceutical formulation according to one of the preceding claims, characterized in that the formulation is produced by build-up and/or break-down granulation, preferably by spray granulation.

5

19. Pharmaceutical formulation according to one of claims 1 to 17, characterized in that the formulation is produced by extrusion.

20. Storage stable pharmaceutical formulation comprising at least one
10 active compound in a sustained release matrix,
characterized in that the matrix is a substantially non-swellable diffusion matrix whose release characteristics are determined by amounts of ethylcellulose or an ethylcellulose-based polymer and at least one fatty alcohol as matrix components, and by extrusion or granulation of the matrix materials together with the amount of
15 the active compounds for formation of an active compound-containing matrix.

21. Storage stable pharmaceutical formulation according to claim 20, wherein the diffusion matrix is a substantially non-erosive matrix.

20 22. Storage stable pharmaceutical formulation according to claim 20 or 21, wherein the matrix material contains ethylcellulose.

23. Storage stable pharmaceutical formulation according to one of claims 20 to 22, wherein the matrix is formed by extrusion, particularly by melt extrusion.

25

24. Storage stable pharmaceutical formulation having an effective amount of an opioid agonist and/or an opioid antagonist in a substantially non-swellable and non-erosive diffusion matrix, whose release characteristics are determined by amounts of ethylcellulose or an ethylcellulose-based polymer and at least one fatty
30 alcohol.

- 63 -

25. Storage stable pharmaceutical formulation according to claim 24 having an effective amount of oxycodone and/or naloxone, with oxycodone being present in an amount ranging from 10 to 150 mg, preferably from 10 to 80 mg and
5 naloxone being present in an amount ranging from 1 to 50 mg per unit dosage.

26. Storage stable pharmaceutical formulation according to claim 24 or 25 having an effective amount of oxycodone and/or naloxone, wherein oxycodone and naloxone are present in a weight ratio ranging from maximal 25:1, preferably
10 maximal 20:1, 15:1, particularly preferably 5:1, 4:1, 3:1, 2:1 and 1:1.

27. Method for producing a formulation according to one of claims 1 to 26,
characterized in that granulation, preferably build-up and/or break-down
15 granulation, particularly preferably spray granulation is used.

28. Method of producing a formulation according to one of claims 1 to 26, being an extrusion method, wherein counter-rotating or co-rotating single or multiple screw extruders with/without kneading elements are used.
20

29. Method according to claim 28, being an extrusion method wherein counter-rotating twin-screw extruders, preferably without kneading elements, are used.

25 30. Method according to claim 28 or 29, characterized in that the temperature of the heating zones of the extruders is between 20°-120°C, preferably between 50°-100°C, more preferably between 50°-90°C and even more preferably between 50°-70°C.

30

- 64 -

31. Method according to one of claims 28 to 30,
characterized in that the diameter of the nozzle on the extruder is between 1 to 10
mm, preferably between 2 to 8 mm and particularly preferably between 3 to 5 mm.

5 32. Method according to one of claims 28 to 31,
characterized in that the resulting temperature in the extruder does not influence
the stability of the active compounds.

33. Method of producing a pharmaceutical dosage form for the treatment
10 of opioid-induced side effects, **characterized in that**
the pharmaceutical dosage form comprises a pharmaceutical formulation according
to one of claims 1 to 10.

34. Method according to claim 33, **characterized in that**
15 the preparation is used for treatment of opioid-induced obstipation and preferably for
treatment of opioid-induced pruritus.

35. Method of producing a pharmaceutical dosage form for the treatment
of idiopathic syndromes, **characterized in that**
20 the pharmaceutical dosage form comprises a pharmaceutical formulation according
to one of claims 1 to 10.

36. Method according to claim 35, **characterized in that**
the preparation is used for treatment irritable bowel syndrome, preferably for
25 treatment of idiopathic pruritus or pruritus due to cholestasia and/or renal
dysfunction.

- 65 -

37. Method according to one of claims 33 to 36, **characterized in that** the matrix is a substantially non-swellable diffusion matrix whose release characteristics are determined by amounts of ethylcellulose or an ethylcellulose-based polymer and of at least one fatty alcohol.

5

38. Method according to one of claims 33 to 37, **characterized in that** the preparation comprises between approximately 1 to 50 mg naloxone, preferably between approximately 5 to 30 mg naloxone and even more preferably between approximately 5 to 20 mg naloxone.

10

39. Method according to one of claims 33 to 38, **characterized in that** naloxone is present in the form of its pharmaceutically acceptable and equally active derivatives, such as the free base, salts and the like, preferably as the hydrochloride, sulfate, bisulfate, tatarate, nitrate, citrate, bitartrate, phosphate, malate, maleate, hydrobromide, hydroiodide, fumarate or succinate.


15

40. Method according to one of claims 33 to 39, **characterized in that** the matrix is produced by extrusion.

20


1/19

Figure 1A




2/19

Figure 1B




3/19

Figure 2




4/19

Figure 3A



5/19

Figure 3B




6/19

Figure 4A



7/19

Figure 4B



8/19

Figure 5A: Surface of a Ox/Nal-10 tablet at 25x magnification. The voltage was 10 kV. The bar length corresponds to 2 mm.





Figure 5B: Surface of a Ox/Nal-10 tablet at 200x magnification. The voltage was 10 kV. The bar length corresponds to 200 μ m.



9/19

Figure 6A: Surface of a Oxy/Nal-Extr tablet at 40x magnification. The voltage was 10 kV. The bar length corresponds to 700 μm .





Figure 6B: Surface of a Oxy/Nal-Extr tablet at 200x magnification. The voltage was 10 kV. The bar length corresponds to 300 μm .



10/19

Figure 7A: Surface of a Valoron® N tablet at 25x magnification. The voltage was 10 kV. The bar length corresponds to 2 mm.






Figure 7B: Surface of a Valoron® N tablet at 100x magnification with crystal (Tilidine, down left). The voltage was 10 kV. The bar length corresponds to 500 μ m.




11/19

Figure 8A




12/19

Figure 8B



13/19

Figure 9



14/19

Figure 10A: Surface of a Nal-5-Eud tablet at 25x magnification- The voltage was 10 kV. The bar length corresponds to 2mm.





Figure 10B: Surface of a Nal-5-Eud tablet at 200x magnification. The voltage was 10 kV. The bar length corresponds to 200µm.



15/19

Figure 11A: Surface of a Nal-Extr tablet 25x magnification. The voltage was 10 kV. The bar length corresponds to 2mm.





Figure 11B: Surface of a Nal-Extr tablet at 200x magnification. The voltage was 10 kV. The bar length corresponds to 200 μ m.



16/19

Figure 12A: Surface of Nal-10-Sure granulates at 30x magnification. The voltage was 10 kV. The bar length corresponds to 1 mm.




Figure 12B: Surface of Nal-10-Sure granulates at 200x magnification. The voltage was 10 kV. The bar length corresponds to 100 μ m.



17/19

Figure 13A: Surface of Nal-Extr granulates at 30x magnification. The voltage was 10 kV. The bar length corresponds to 1 mm.




Figure 13B: Surface of Nal-Extr granulates at 200x magnification. The voltage was 10 kV. The bar length corresponds to 100 μ m.




18/19

Figure 14A



19/19

Figure 14B



THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)